抗人ALK-1参考抗体

Anti-Human ALK-1 Reference Antibody

货号：RB9T37015234

在您使用本产品前请认真阅读说明书，这对您顺利完成实验很有帮助。

产品编码
RB9T37015234

中文名称
抗人ALK-1参考抗体

英文名称
Anti-Human ALK-1 Reference Antibody

形态
Liquid

纯度
>95% purity as determined by SDS-PAGE.

内毒素水平
Please contact the lab for this information.

应用
ELISA, WB, Bioactivity: FACS, Functional assay, Research in vivo

表达系统
Mammalian Cells

登录号
P37023

宿主种属
Human

克隆性
Monoclonal

抗体亚型
IgG2-kappa

纯化方式
Protein A/G purified from cell culture supernatant.

浓度
1mg/ml

种属反应性
Human

靶标	产品使用说明
Serine/threonine-protein kinase receptor R3, ACVRL1, Activin receptor-like kinase 1, ALK-1, ACVRLK1, ALK1, SKR3, TGF-B superfamily receptor type I, TSR-I	ELISA: 1:2000-1:20000; WB: 1:500-1:2000

背景信息

Ascrinvacumab, also known as PF-03446962 or anti-hALK1 antibody, is a human immunoglobulin G (IgG) 2 monoclonal antibody which can be used as therapeutic antibody drug for the treatment of many tumors. It has been found that the clinical trials of ascrinvacumab has been developed in cancers including advanced solid tumors, urothelial cell carcinoma, hepatocellular carcinoma, and mesothelioma. Ascrinvacumab can binding to ACVRL1 by recognizing the extracellular domain of ACVRL1. ACVRL1, also called activin receptor-like kinase 1 (ALK1), is a transforming growth factor β (TGF-β) type I receptor. Ascrinvacumab is a fully human monoclonal antibody generated by immunizing the IgG 2 transgenic XenoMouse. In a human/mouse chimera tumor model, ascrinvacumab decreased human vessel density and improved antitumor efficacy when combined with bevacizumab (anti-VEGF). It suggests that ascrinvacumab therapy may be complementary to anti-VEGF in cancer intervention. As early as 2012, researchers had investigated the effects of ascrinvacumab on endothelial cell function. And the results showed that ascrinvacumab do interferes with the endothelial cell sprouting induced by Bone Morphogenetic Protein 9 (BMP9). A phase 2 trial study of ascrinvacumab in pre-treated patients with urothelial cancer had been reported in 2014. In addition, its treatment results of advanced solid tumors, hepatocellular carcinoma, and advanced malignant pleural mesothelioma also had been reported in 2016. In addition to advanced malignant pleural mesothelioma, ascrinvacumab shows the value of continuing treatment evaluation in the other two diseases.

别名

PF-03446962, 1463459-96-2

储存缓冲液

0.01M PBS, pH 7.4.

稳定性和储存

Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4° C for short-term storage (1-2 weeks). Store at -20° C for up to 12 months. For long-term storage, store at -80° C.

For research use only. Not suitable for clinical or therapeutic use.